RCKT
Rocket Pharmaceuticals IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Value
$2.39-2.05%
Close Nov 6, 2026
- Market cap
- $260.43M
- 1 month
- -9.3%
- 3 months
- -34.5%
- 1 year
- -28.2%
- 52-week range
- $2.18$5.30
- Dividend
- No payments on record
- Next-quarter EPS estimate
- -$0.41Quarter to Sep 30, 2026 · 5 analysts · revenue $181.82K · 0.0% in 30d
- Short interest
- 18.6% of float16.3M shares · settled Oct 15, 2026 · +8.2% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$17.25M
- Free cash flow
- -$170.4M
- Book value
- $368.83M
- Total debt
- $24.8M
- P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- FCF yield
- -65.4%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Read more
It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
- Website
- rocketpharma.com
- Headquarters
- Cranbury, NJ, United States
- Employees
- 202
- Listed
- Feb 18, 2015
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 22, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 10, 2026 | — | — | — | -$46.9M | $123.2M |
| Mar 2026filed May 7, 2026 | — | — | — | -$48.5M | -$47.6M |
| Dec 2025filed Feb 26, 2026 | — | — | — | -$44.0M | -$42.5M |
| Sep 2025filed Nov 6, 2025 | — | — | — | -$52.2M | -$50.3M |
| Jun 2025filed Aug 7, 2025 | — | — | — | -$71.1M | -$68.9M |
| Mar 2025filed May 8, 2025 | — | — | — | -$64.4M | -$61.3M |
| Dec 2024filed Feb 27, 2025 | $9.2M | -10.9% | 50.0% | -$62.7M | -$60.3M |
| Sep 2024filed Nov 7, 2024 | — | — | — | -$69.4M | -$66.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 26, 2026 | — | — | — | -$228.5M | -$223.1M |
| Dec 2024filed Feb 27, 2025 | — | — | — | -$273.2M | -$258.7M |
| Dec 2023filed Feb 27, 2024 | — | — | — | -$259.7M | -$245.6M |
| Dec 2022filed Feb 28, 2023 | — | — | — | -$224.3M | -$221.9M |
| Dec 2021filed Feb 28, 2022 | — | — | — | -$167.2M | -$169.1M |
| Dec 2020filed Mar 1, 2021 | — | — | — | -$136.0M | -$146.7M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched RCKT. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
16,281,767 shares short
+1,231,987 shares (+8.2%) vs Sep 30, 2026
18.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
15,049,780 shares short
+202,302 shares (+1.4%) vs Sep 15, 2026
17.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
14,847,478 shares short
+135,526 shares (+0.9%) vs Aug 31, 2026
16.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
14,711,952 shares short
+320,633 shares (+2.2%) vs Aug 14, 2026
16.8% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
14,391,319 shares short
-1,104,188 shares (-7.1%) vs Jul 31, 2026
16.4% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
15,495,507 shares short
-1,076,360 shares (-6.5%) vs Jul 15, 2026
17.7% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind RCKT’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 4 · reverse split
Effective Jan 5, 2018
Each 4 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if RCKT is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
26 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 29, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 53 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 12
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
180 filers reported a long position in RCKT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
61.6%
of the 99.7M shares 13-F filers reported
Moves vs Q1 2026
8 added1 trimmed
1 unchanged
Net shares held
+11.5%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | $60.5M · 17.7M shares | 17.7M | Unchanged |
| 2 | BlackRock, Inc. | $33.9M · 9.9M shares | 9.9M | +26.7% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $19.9M · 5.8M shares | 5.8M | +23.9% |
| 4 | CITIGROUP INC | $16.6M · 4.9M shares | 4.9M | -4.7% |
| 5 | MARSHALL WACE, LLP | $13.8M · 4M shares | 4M | +32.6% |
| 6 | MILLENNIUM MANAGEMENT LLC | $13.7M · 4M shares | 4M | +28.3% |
| 7 | Newtyn Management, LLC | $13.7M · 4M shares | 4M | +26.3% |
| 8 | MAVERICK CAPITAL LTD | $13.4M · 3.9M shares | 3.9M | +10% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | $12.9M · 3.8M shares | 3.8M | +0.2% |
| 10 | AQR CAPITAL MANAGEMENT LLC | $11.6M · 3.4M shares | 3.4M | +10.3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of RCKT file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 30, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive · amended | 1.33%under 5% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for RCKT
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.